Eloxx Pharmaceuticals Inc. presented latest data from its ribosomal-modulating agent program for cancer therapy.

Researchers have identified an RNA-binding protein that played a role in colon cancer relapse, offering new insights into how cells persist in the presence of chemotherapy.